ClearPoint Neuro, Inc. (CLPT)

ClearPoint Neuro completed the acquisition of Irras Holdings Inc. for $27.5 million on November 6, 2025, and released its Q3 2025 earnings. On March 17, 2026, the company reported its Q4 and full-year 2025 results, with Q4 earnings per share missing analysts' consensus estimates. In early 2026, the stock experienced pressure due to weaker 2026 financial guidance and uncertainty regarding the FDA's stance on gene therapies. On April 20, 2026, ClearPoint Neuro announced Canadian approval for its Neuro Navigation System. On April 22, 2026, the company announced FDA clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and its first clinical use. The stock experienced a 25% gain in the month preceding May 6, 2026. On May 8, 2026, Stifel reinstated its coverage of ClearPoint Neuro with a Buy rating and a target price of $16. ClearPoint Neuro's stock had decreased by 6.3% since January 1, 2026, as of May 9, 2026. The company is scheduled to announce its first-quarter 2026 results on May 13, 2026.

Information regarding specific demand seasonality for ClearPoint Neuro, Inc.'s products and services was not found in the provided search results.

ClearPoint Neuro, Inc. is a medical device company focused on enabling precise navigation for device, cell, and gene therapies targeting the brain and spine. The company develops and commercializes integrated systems for minimally invasive neurosurgical procedures, leveraging real-time MRI guidance. Its business is structured around four growth pillars: pre-commercial biologics and drug delivery, neurosurgery navigation, laser therapy and access, and intracranial fluid management. Major products and services include the ClearPoint Neuro Navigation System, ClearPoint Prism Neuro Laser System, SmartFlow Neuro Cannula, IRRAflow System, ClearPoint Services and Disposables, and Biologics and Drug Delivery Services.

ClearPoint Neuro is actively engaged with healthcare and research centers across North America, Europe, Asia, and South America. The company has expanded its regulatory network to 34 countries, including recent Canadian approval for its Neuro Navigation System.

The name "ClearPoint" is synonymous with precision-guided neurosurgery. Recent FDA clearance for its Velocity Alpha(R) MR High Speed Surgical Drill System and Canadian approval for its Neuro Navigation System contribute positively to its reputation. However, an Ethos ESG impact scorecard rated ClearPoint Neuro with an overall 'C' (51.0).

ClearPoint Neuro, Inc. has a diverse ownership structure, including institutional, individual, and retail investors. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., and Geode Capital Management, Llc, holding approximately 38.17% of the stock. Bruce C. Conway is the largest individual shareholder, owning 13.49% of the company's shares, with insiders collectively owning about 25.86% of the company. The general public holds a significant portion, around 35.97% to 51% of ClearPoint Neuro shares.